Director, Global Value, Access & Pricing – CRC

Benefits

Parental leave

Not verified

Non-birth-parent leave

Not verified

Family-building benefits

• Fertility benefits: Not verified
• Adoption assistance: Not verified
• Surrogacy assistance: Not verified

Mental health support

Not verified

Relocation assistance

Not verified

Childcare support

Not verified

Learning budget

Not verified

Verification

Not verified

Salary

$201K-$251K not verified - source not recorded; timestamp not recorded

401(k) match

Not verified

Was this benefit information wrong? Tell us.

Market context

U.S. role benchmark (BLS OEWS)

$93,011 U.S. median for this role

Projected growth (BLS Employment Projections)

+5.1% - Faster than average

143% above the BLS role benchmark for marketing aggregate.

Matched to SOC 13-1161 - Marketing aggregate by role bucket.

Source: U.S. Bureau of Labor Statistics, OEWS, May 2024 and Employment Projections, 2024-2034.

Schedule

Shift type

Not verified

Weekend work

Not verified

Application

Cover letter

Not verified

Assessment

Not verified

Deadline

Not stated

Where they hire

State eligibility is not yet verified.

About this role

Director, Global Value, Access & Pricing – CRC Remote (United States) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Director, Global Value, Access & Pricing - CRC is responsible for developing and driving global access and pricing strategies for Revolution Medicines' CRC assets to enable timely, sustainable patient access across key markets. This role ensures payer and HTA requirements are embedded into clinical development, indication sequencing, and launch planning from early-stage development through commercialization. The Director serves as the global access lead on cross-functional asset teams and partners closely with HEOR, Clinical Development, Regulatory, Commercial, Finance, and Regional Market Access to align global strategy with regional execution. Key responsibilities: - Lead development of global pricing and market access strategies for CRC assets, including launch sequencing, reference pricing considerations, and price corridor management across priority markets. - Identify payer-relevant evidence requirements and partner with HEOR to align evidence generation plans with global reimbursement needs. - Assess CRC competitive dynamics, including

Read the full description at www.revmed.com. FewerJobs shows a source-linked preview and links to the original posting.